{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02869243: Phase 1 Interventional Completed Glioblastoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:visepegenatide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04460885: Phase 3 Interventional Completed Diabetes Mellitus, Type 2
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00471120: Not Applicable Interventional Terminated Uterine Cancer
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04523220: Phase 2 Interventional Completed End-stage Renal Disease
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:nomlabofusp [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:praluzatamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03795142: Early Phase 1 Interventional Completed Healthy Volunteers
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03464032: Phase 1 Interventional Unknown status Melanoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03287908: Phase 1 Interventional Terminated Relapsed/Refractory Multiple Myeloma
(2017)
Source URL:
Class:
PROTEIN
